Document is current

Article History

Received: 21 October 2023

Accepted: 2 September 2024

First Online: 14 October 2024

Declarations

:

: The current trial was conducted in accordance with the Declaration of Helsinki, was approved by the ethical approval committee of Zanjan University of Medical Sciences, Zanjan, Iran, and is registered with the code IR.ZUMS.REC.1395.226. It has also been registered on the clinical trial website with the registration number IRCT2015110824947N1 on 6/02/2017. Patients were informed about the advantages and disadvantages of the study before signing the confidential written consent letter to enroll in the study. Written informed consent was obtained from all participants to participate in the study. The participants took part in the study voluntarily. The participants experienced no financial burden, as they had full insurance coverage. The participants were assured that all tissue-transmissible diseases, such as viral infections (including HTLV, CMV, HBV, HCV, and HIV), bacterial and fungal infections, and allergic reactions, were screened by the manufacturer of the hAM. The researchers were guaranteed the ability to support and treat participants free of charge if any potential side effects caused by SSDZ or hAM occurred. The involved hospital and ward were informed of the results of the study. The data used in this study were anonymized before use.

: Not applicable.

: The authors declare no conflicts of interest.